359 related articles for article (PubMed ID: 28314837)
1. Risk-Reducing Strategies for Ovarian Cancer in
Tschernichovsky R; Goodman A
Oncologist; 2017 Apr; 22(4):450-459. PubMed ID: 28314837
[TBL] [Abstract][Full Text] [Related]
2. Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1 and BRCA2 mutations.
Smith MJ; Gerber D; Olsen A; Khouri OR; Wang Y; Liu M; Smith J; Pothuri B
Am J Obstet Gynecol; 2021 Nov; 225(5):508.e1-508.e10. PubMed ID: 34171390
[TBL] [Abstract][Full Text] [Related]
3. TUBectomy with delayed oophorectomy as an alternative to risk-reducing salpingo-oophorectomy in high-risk women to assess the safety of prevention: the TUBA-WISP II study protocol.
Steenbeek MP; van Bommel MHD; intHout J; Peterson CB; Simons M; Roes KCB; Kets M; Norquist BM; Swisher EM; Hermens RPMG; ; Lu KH; de Hullu JA
Int J Gynecol Cancer; 2023 Jun; 33(6):982-987. PubMed ID: 37045546
[TBL] [Abstract][Full Text] [Related]
4. Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations.
Nebgen DR; Hurteau J; Holman LL; Bradford A; Munsell MF; Soletsky BR; Sun CC; Chisholm GB; Lu KH
Gynecol Oncol; 2018 Jul; 150(1):79-84. PubMed ID: 29735278
[TBL] [Abstract][Full Text] [Related]
5. Systematic review of acceptability, cardiovascular, neurological, bone health and HRT outcomes following risk reducing surgery in BRCA carriers.
Gaba F; Manchanda R
Best Pract Res Clin Obstet Gynaecol; 2020 May; 65():46-65. PubMed ID: 32192936
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers.
Kwon JS; Tinker A; Pansegrau G; McAlpine J; Housty M; McCullum M; Gilks CB
Obstet Gynecol; 2013 Jan; 121(1):14-24. PubMed ID: 23232752
[TBL] [Abstract][Full Text] [Related]
7. Satisfaction with prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers is very high and little dependent on the participants' characteristics at surgery: a prospective study.
Grandi G; Sammarini M; Cortesi L; Toss A; Botticelli L; Varliero F; Sighinolfi G; Barbieri E; Facchinetti F
Menopause; 2021 Feb; 28(3):263-270. PubMed ID: 33534430
[TBL] [Abstract][Full Text] [Related]
8. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a patient decision aid for BRCA1/2 pathogenic variant carriers choosing an ovarian cancer prevention strategy.
Steenbeek MP; van Bommel MHD; Harmsen MG; Hoogerbrugge N; van Doorn HC; Keurentjes JHM; van Beurden M; Zweemer RP; Gaarenstroom KN; Penders CGJ; Brood-van Zanten MMA; Vos MC; Piek JM; van Lonkhuijzen LRCW; Apperloo MJA; Coppus SFPJ; IntHout J; de Hullu JA; Hermens RPMG
Gynecol Oncol; 2021 Nov; 163(2):371-377. PubMed ID: 34456057
[TBL] [Abstract][Full Text] [Related]
10. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status.
Manchanda R; Abdelraheim A; Johnson M; Rosenthal AN; Benjamin E; Brunell C; Burnell M; Side L; Gessler S; Saridogan E; Oram D; Jacobs I; Menon U
BJOG; 2011 Jun; 118(7):814-24. PubMed ID: 21392246
[TBL] [Abstract][Full Text] [Related]
11. Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea.
Kim SI; Lim MC; Lee DO; Kong SY; Seo SS; Kang S; Lee ES; Park SY
J Cancer Res Clin Oncol; 2016 Jan; 142(1):333-40. PubMed ID: 26438354
[TBL] [Abstract][Full Text] [Related]
12. Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future.
Hirasawa A; Masuda K; Akahane T; Tsuruta T; Banno K; Makita K; Susumu N; Jinno H; Kitagawa Y; Sugano K; Kosaki K; Aoki D
Jpn J Clin Oncol; 2013 May; 43(5):515-9. PubMed ID: 23487443
[TBL] [Abstract][Full Text] [Related]
13. Cancer worry among BRCA1/2 pathogenic variant carriers choosing surgery to prevent tubal/ovarian cancer: course over time and associated factors.
van Bommel MHD; Steenbeek MP; IntHout J; Hermens RPMG; Hoogerbrugge N; Harmsen MG; van Doorn HC; Mourits MJE; van Beurden M; Zweemer RP; Gaarenstroom KN; Slangen BFM; Brood-van Zanten MMA; Vos MC; Piek JM; van Lonkhuijzen LRCW; Apperloo MJA; Coppus SFPJ; Prins JB; Custers JAE; de Hullu JA
Support Care Cancer; 2022 Apr; 30(4):3409-3418. PubMed ID: 34997316
[TBL] [Abstract][Full Text] [Related]
14. Perceptions of risk and reward in BRCA1 and BRCA2 mutation carriers choosing salpingectomy for ovarian cancer prevention.
Ghezelayagh TS; Stewart LE; Norquist BM; Bowen DJ; Yu V; Agnew KJ; Pennington KP; Swisher EM
Fam Cancer; 2020 Apr; 19(2):143-151. PubMed ID: 32096072
[TBL] [Abstract][Full Text] [Related]
15. Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study.
Harmsen MG; Arts-de Jong M; Hoogerbrugge N; Maas AH; Prins JB; Bulten J; Teerenstra S; Adang EM; Piek JM; van Doorn HC; van Beurden M; Mourits MJ; Zweemer RP; Gaarenstroom KN; Slangen BF; Vos MC; van Lonkhuijzen LR; Massuger LF; Hermens RP; de Hullu JA
BMC Cancer; 2015 Aug; 15():593. PubMed ID: 26286255
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers: what is going on in a region of northern Italy?
Grandi G; Perrone AM; Perrone A; Mandato VD; Comerci G; Sammarini M; Merisio C; Amadori A; Stefanetti M; Martinello R; Facchinetti F; De Iaco P;
Maturitas; 2021 Jan; 143():59-64. PubMed ID: 33308637
[TBL] [Abstract][Full Text] [Related]
17. Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers: A Nonrandomized Controlled Trial.
Steenbeek MP; Harmsen MG; Hoogerbrugge N; de Jong MA; Maas AHEM; Prins JB; Bulten J; Teerenstra S; van Bommel MHD; van Doorn HC; Mourits MJE; van Beurden M; Zweemer RP; Gaarenstroom KN; Slangen BFM; Brood-van Zanten MMA; Vos MC; Piek JMJ; van Lonkhuijzen LRCW; Apperloo MJA; Coppus SFPJ; Massuger LFAG; IntHout J; Hermens RPMG; de Hullu JA
JAMA Oncol; 2021 Aug; 7(8):1203-1212. PubMed ID: 34081085
[TBL] [Abstract][Full Text] [Related]
18. Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation.
Guidozzi F
Climacteric; 2016 Oct; 19(5):419-22. PubMed ID: 27426853
[TBL] [Abstract][Full Text] [Related]
19. Surgical decision making in premenopausal
Gaba F; Goyal S; Marks D; Chandrasekaran D; Evans O; Robbani S; Tyson C; Legood R; Saridogan E; McCluggage WG; Hanson H; Singh N; Evans DG; Menon U; Manchanda R;
J Med Genet; 2022 Feb; 59(2):122-132. PubMed ID: 33568437
[TBL] [Abstract][Full Text] [Related]
20. Acceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers.
Holman LL; Friedman S; Daniels MS; Sun CC; Lu KH
Gynecol Oncol; 2014 May; 133(2):283-6. PubMed ID: 24582866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]